Immunotherapy combo slows advanced lung cancer in major trial
NCT ID NCT03607539
First seen May 13, 2026 · Last updated May 24, 2026 · Updated 2 times
Summary
This study tested whether adding the immunotherapy drug sintilimab to standard chemotherapy helps people with advanced or spreading non-squamous non-small cell lung cancer. About 400 adults who had not received prior treatment took part. The combination delayed cancer growth compared to chemotherapy alone, but ongoing treatment is needed, so this is a disease control approach, not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sun Yat-Sen University Cancer Center
Guangzhou, China
Conditions
Explore the condition pages connected to this study.